Halozyme Therapeutics, Inc. (NASDAQ: HALO) has announced the appointment of David Ramsay as the interim Chief Financial Officer, effective March 23, 2026. Ramsay, who previously served as the company's CFO from 2003 to 2009 and again from 2013 to 2015, brings with him over 30 years of strategic financial leadership in the biotechnology and life sciences sectors.
During his prior tenure as CFO, under Ramsay's guidance, the company evolved from a private enterprise to a billion-dollar public biopharmaceutical company. This time around, he will oversee all financial operations as the company actively searches for a permanent CFO.
In addition to Ramsay's appointment, Halozyme is currently engaged in an executive search for a permanent Chief Financial Officer and has engaged a leading executive search firm to identify candidates with expertise in capital markets and strategy.
Halozyme is known for its Enhance® drug delivery technology with the proprietary enzyme rHuPH20, which has facilitated the subcutaneous delivery of injected drugs and fluids, impacting over one million patient lives through ten commercialized products across over 100 global markets. The company's expanded drug delivery technology portfolio includes partner products using HyperCon™ and Surf Bio's hyperconcentration technology.
Furthermore, Halozyme develops, manufactures, and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability, and tolerability, enhancing patient comfort and adherence. The company has two proprietary commercial products, Hylenex® and Xyosted®, partnered commercial products, and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
The market has reacted to these announcements by moving the company's shares -0.85% to a price of $71.21. Check out the company's full 8-K submission here.
